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Abstract 
Six analogues of a known non-nucleoside HIV reverse transcriptase inhibitor were 
synthesized. Modifications to the parent compound, (±)-3-phenyl-2-methyl-2,3-
dihydrobenzo[d]isothiazole (NSC-I08406), yielded compounds of varying potency (ICso 
from 2 to >200 J.LM). The most potent inhibitor, (±)-3-(3-chlorophenyl)-2-methyl-2,3-
dihydrobenzo[d]isothiazole, was also separated into its enantiomers using a chiral 
column. The (+ )-(S) was found to be the active enantiomer, with ECso of 0.086 J.LM. 
Introduction 
In the early 1980s the cause of AIDS was still unknown. Viruses became the 
primary suspect in the search, but that still left many possible types-retroviruses, 
parvoviruses, herpesviruses-that all may cause immune deficiency. The scope was 
narrowed to retroviruses beginning with the work of Barre-Sinoussi et al. in ,1983, who 
isolated a viral reverse transcriptase from a patient with lymphadenopathy syndrome 
(LAS).l Originally this virus was hypothesized to be a member of the human T-cell 
leukemia virus (HTLV) group due to its similar characteristics. Montagnier, Gallo, and 
Levy each contributed to proving that the retrovirus associated with AIDS was distinct 
from HTL V and part of the lentivirus genus. 1 The AIDS virus was designated the human 
immunodeficiency virus (HIV) in 1986 by the International Committee on Taxonomy of 
Viruses. 1 
HIV exhibits characteristics common to alilentiviruses. Molecularly,lentiviruses 
have a large genome, a highly glycosylated envelope protein, and are polymorphic. 
Biologically, they infect macrophages, inside of which there is an accumulation of 
unintegrated viral DNA. Clinically, the disease often shows a long incubation period 
with latent infection of cells. Immune suppression, central nervous system problems, 
arthritis, and autoimmunity all show associations with these viruses. 1 
The incentives for developing treatments for HIV is obvious. The number of 
infected individuals continues to grow rapidly, with about 10 million in 1993, 21 million 
in 1996, and 33.4 million in 1998 worldwide.2-4 The best approach to treatment is not 
clear. Drugs have been, and continue to be, developed to halt viral replication processes 
or block virus attachment to cells. Gene therapy, antioxidants, and destruction of virus-
infected cells with antibody-linked toxins have been attempted. Immune stimulation by 
injection of viral protein or various forms of vaccination are being evaluated. 1 Slowing 
the progression of the disease is the most that is hoped for with most of these treatments. 
Understanding of the life cycle of HIV offers insights into how it may be 
disrupted. The first step of inf~~~ion of healthy cells begins with the interaction of a viral 
surface envelope protein, gp 120, with a CD4 or- other receptor on the cell surface. Thus, 
CD4+ helper T lymphocytes are often infected, but many other cell types, including cells 
in the blood, brain, skin, bowel, and elsewhere, are also susceptible. Following 
attachment, other envelope domains are exposed or cleaved to promote fusion with the 
cell membrane. 1 
Once fused with the cell, three enzymes-reverse transcriptase, integrase, and 
protease-play key roles in bringing about the replication and processing of the viral 
genome. HIV's genetic material is in the form of RNA. In order to insert itself into the 
production machinery of the cell, viral RNA must first be made into a double-stranded 
DNA copy (cDNA). The HIV reverse transcriptase, which enters the cytoplasm along 
with the viral RNA, performs this function.2 The cDNA travels to the cell's nucleus, 
where an integrase enzyme incorporates it into the DNA of the host. At this point the cell 
processes the cDNA just as it does its own. The inserted cDNA is transcribed to produce 
viral mRN A and viral genomic RNA. Viral mRN A is translated by the cell to create all 
the viral proteins. 1 Some of these proteins, such as Gag, which functions in virus 
structure and matrix, and the reverse transcriptase, must then be modified to be fully 
functional. This modification is accomplished with a protease enzyme.5 Viral genomic 
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RNA and proteins are packaged into a capsid on the cell membrane. New virus particles 
are then released through the cell membrane by budding off of the capsid. 
Review of HIV Reverse Transcriptase Treatments 
All three of the enzymes necessary for HIV replication have become targets for 
tr~ating an infection. Integrase inhibitors are just beginning to be explored, but drugs that 
inhibit either the protease or reverse transcriptase enzymes have been approved for use 
for some time. Because of toxicity of some treatments and rapidly emerging resistant 
viral strains, the need for new drugs still exists. 
The HIV reverse transcriptase enzyme makes a good therapeutic target since it 
plays no role in host cell life, and is only produced and utilized by the virus. HIV reverse 
transcriptase is also the most thoroughly studied of the three major viral enzymes. It is a 
heterodimer consisting of a 66 kDa subunit and a 51 kDa subunit, each of which contains 
four subdomains. Crystal structures have shown that the molecule's subdomains are quite 
flexible. The polymerase activity of the enzyme is carried out by the p66 subunit, with 
the subdomains folding to position the template-primer.5 
Reverse transcriptase inhibitors fall into two major categories based on their 
structure and mode of action: nucleoside and non-nucleoside. Nucleoside inhibitors were 
the first class developed and include compounds, such as AZT, ddI, and ddC, that have 
already been approved and are in clinical use.6 These inhibitors only become functional 
following phosphorylation by host cell kinases into triphosphate nucleoside analogs. 
Once phosphorylated, they can replace the normal substrate of reverse transcriptase, and 
their incorporation leads to chain termination, due to lack of a site for 3'-phosphorylation 
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on the sugar moiety. Nucleoside inhibitors have a variety of side effects, including bone 
marrow suppression, peripheral neuropathy, and mitochondrial myopathy.2 
Non-nucleoside inhibitors function in a different manner. Three possible 
mechanisms of action have been proposed: inhibition by indirectly changing the 
conformation of the enzyme active site, binding of the drug hinders subdomain 
movement, or binding causes the positioning of the primer strand to be altered. Studies 
using crystallographic data show that the first of these possibilities is the most likely. All 
non-nucleoside inhibitors have been shown to bind in a "butterfly" conformation at a site 
near the active site on the p66 unit. Non-nucleoside reverse transcriptase inhibitors have 
several advantages over the nucleoside drugs. They are generally nontoxic, highly 
potent, and highly specific.5 Compounds in this class are numerous, including HEPT, 
TIBO, nevirapine, and pyridones.7 Non-nucleoside and nucleoside compounds may even 
be used together to achieve synergistic results.6 
Perhaps the greatest problem with the use of these drugs is that the virus may 
rapidly become resistant. HIV has a rapid replication rate (108-109 new virions produced 
per day) and a high error rate for translation of the reverse transcriptase enzyme (1 in 
1 0000 bases). Both of these characteristics contribute to a rapid mutation and selection 
process. New mutants, with only a 5% advantage, are estimated to become dominant 
within around 100 viral generations.5 Because all the non-nucleoside inhibitors bind at a 
common site, the assumption might be that a mutant resistant to one drug would also be 
resistant to the others. Fortunately, this has been shown to not be the case. A mutation 
that causes resistance to one compound may actually disrupt another resistance mutation 
for a different compound.8 
4 
These observations on mutation and resistance has led to the strategy of using 
combinations of drugs in the treatment of HIV. Combinations of inhibitors for the 
protease, reverse transcriptase, and integrase enzymes are often very effective. In 
addition, combinations of reverse transcriptase inhibitors that cause offsetting mutations 
are sought. 5 Here we describe the synthesis of several analogues of a known non-: .. ' 
nucleoside HIV reverse transcriptase inhibitor, with the aim of developing a more potent 
compound that would be worthy of clinical development. 
Results and Discussion 
Molecular modeling work by the NCI using the HIV reverse transcriptase enzyme 
gave likely parameters for inhibitory compounds. (±)-3-phenyl-2-methyl-2,3-
dihydrobenzo[d]isothiazole (NSC-108406) (Fig. 1) was one compound that matched 
NSC-108406 
Figure 1 
these parameters. Substituent modifications could be made to either benzene ring, at the 
chiral carbon, or the nitrogen. This work includes compounds with modifications at the 
Figure 2 
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positions shown in Fig. 2. 
The syntheses of these compounds (Scheme 1) were begun by making either N-
methylbenzenesulfonamide (2) or N-phenylbenzenesulfonamide (13). 
Benzenesulfonylchloride and the appropriate amine (CH3NH2 or PhNH2) mixed under 
basic conditions easily generated the desired product. The N-methylbenzenesulfonamide 
(2) was partially crystallized from CH2Clz and hexane~- but the compound had a tendency 
to return to a syrup. 
Addition of the second benzene ring to 2 or 13 and subsequent closing of the third 
ring was accomplished by two steps.9 Treatment of the benzene sulfonamide with 2 
equivalents of n-butyllithium produced the dianion in Fig. 3. A suitably substituted 
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Figure 3 
benzaldehyde was then added and following workup with dilute acid workup, a carbinol 
sulfonamide was acquired (3, 5, 7, 9, 11, 14). These products often crystallized after 
purification. 
The sultam product was generated by cyclization with concentrated sulfuric acid 
(4, 6, 8, 10). There were two exceptions to this. Treatment of 14 with concentrated 
sulfuric acid might have caused the removal of the benzene from the nitrogen rather than 
the desired ring closure. Instead, 48% HBr was used for the reaction. Little product 
formation was observed after running the reaction at room temperature. Gentle heating to 
a slow retlux pushed the reaction to the formation of 15. 
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The second exception was with the cyclization of 11. Following reaction with 
concentrated sulfuric acid, the sultone, and not sultam, was created. With the other 
compounds, protonation of the hydroxy group and subsequent loss of the water occurs. 
The strong electron withdrawing influence of the trifluoro group does not permit this, and 
instead the nitrogen is protonated and lost in the ring-closing step. 
Analogues were chosen to test the effect of various substituent characteristics in 
various positions. This work only covers some of the possibilities. Of these compounds, 
halogen substitutions at the R3 position have shown the greatest promise (Table 1; A = 
active, M = moderately active, I = inactive). Both m-chloro- and m-bromo-substituted 
compounds demonstrated excellent inhibition of HIV reverse transcriptase. 
Cmpd. R1 R2 R3 R4 Config. Opt. Rot. mp ECso ICso T1so Activity 
No. (deg) (deg. 2C) (JlM) (JlM) (JlM) 
8 Me H CI H (+/-) 133 0.38 113 297 A 
8a Me H CI H (+}.(S) 166 164 0.086 >2 >31 A 
8b Me H CI H (.}.(R) -150 160 5.28 26.8 5.08 M 
10 Me H Br H (+/-) 128--129 0.781 45.6 58.4 A 
4 Me H H F (+/-) 111--112 37.5 161 4.29 M 
6 Me H H Ph (+/-) 188 >200 I 
15 Ph H H H (+/-) 168--169 >200 I 
Table 1 
All analogues were synthesized without control of the configuration at the lone 
stereocenter. Since enzymes are not only size- and shape-, but also stereospecific, the 
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most active of these compounds (8) was separated into its enantiomers for separate 
biological testing. As expected, a significant increase in activity was observed with one 
enantiomer (8b), which has been identified as the (+ )-(S)-compound. 
Many more analogues of NSC-1 08406 are possible. Any of these compounds 
demonstrating a high degree of inhibition of HN reverse transcriptase may prove useful 
in the treatment of AIDS at some point. The high level of mutation and resistance shown 
by this virus ensures the need for new drugs. 
Experimental 
A. General Methods 
All flash column chromatography was carried out using Silica Gel-60 (230-400 
mesh) and an eluent of 3: 1 hexanes to ethyl acetate. Melting points were determined by 
the capillary method. A Perkin-Elmer Model 241 automatic polarimeter with solutions in 
a 1-dm cell was used to measure optical rotations. 1 Hand l3C NMR spectra were 
obtained on a Bruker AC 250 instrument at 250 MHz and 62.9 MHz, respectively. 
Chemicals were of reagent grade and used without further purification. Solvents were 
distilled and dried using literature procedures. Elemental analyses were done by Atlantic 
Microlabs, Inc. of Atlanta, GA. 
B. Preparation of Compounds 
N-Methylbenzenesulfonamide (2). MeNH2 (6.5 mL, 40% in H20), distilled 
water (65 mL), and NaOH (3.22 g, 80.5 mmol) were mixed in a 250-mL round bottom 
flask and cooled in an ice/water bath to 0 °C. While stirring, PhS02CI (10.3 mL, 80.7 
mmol) was added by syringe over a 5 min period. After 2.5 h, the reaction was warmed 
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to room temperature. The mixture was extracted three times with EtOAc. The organic 
layers were washed with saturated NaCI solution and then dried with magnesium sulfate. 
The solvent was removed under vacuum and purified by chromatography, yielding 12.6 g 
(91.20/0) of 2. IH NMR (CDCh): B 7.87 (2H, m), 7.55 (3H, m), 4.82 (1H, s), 2.65 (3H, s). 
(±)-2-[ (4-Fluorophenyl)hydroxymethyl]~1Y .. methylbenzenesulfonamide (3). 
Dry THF (23.4 mL) was added to N-methylbenzenesulfonamide (2) (1 g, 5.84 mmol) in a 
100-tnL flame-dried round bottom flask. Nitrogen was run into the flask, and the flask 
was cooled to 0 °C while stirring. n-Butyllithium (5.84 mL of a 2.5 M solution in 
hexanes, 14.6 mmol) was then added to the reaction over 3--4 min and left to stir at 0 °C 
for 25 min. To this mixture was added a solution of 4-tluorobenzaldehyde (1.00 mL, 
9.34 mmol) and THF (9.34 mL) over 4 min. This was allowed to stir for 45 min. Next, 
HCI (12 mL, 5% solution) was added, and the two resulting layers were separated. The 
organic layer was washed three times with saturated NaCI solution. The aqueous layers 
were all extracted with ether, and all organic layers were cotnbined. The solution was 
dried with magnesium sulfate, the solvent was removed under vacuum, and the product 
was purified by chromatography, yielding 1.18 g (68.2%) of 3. IH NMR (CDCh): B 7.98 
(lH, m), 7.41 (6H, m), 7.06 (2H, m), 6.70 (lH, s), 4.79 (lH, m), 2.51 (3H, d). 
(±)-3-( 4-Fluorophenyl)-2-methyl-2,3-dihydrobenzo[ d]isothiazole l,l-dioxide 
(4). H2S04 (3 mL) and 3 (300 mg, 1.01 mmo1) were combined in a 50-mL round bottom 
flask. This mixture was then stirred for 1 h. The mixture was poured over ice, rinsing 
the reaction flask with distilled water. This was extracted three times with CH2Ch, and 
all organic fractions were washed with saturated NaCI solution. The solution was dried 
with magnesium sulfate, the solvent was removed under vacuum, and the product was 
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purified by chromatography, yielding 0.2015 g (71.5%) of 4. IH NMR (CDCh): 07.71 
OH, m), 7.41 (2H, m), 7.21 (2H, m), 6.95 (3H, m), 5.10 (1H, s), 2.63 (3H, s); l3C NMR 
(CDCh): 0 138.44, 134.28, 133.40, 132.88, 130.34, 130.22, 129.78, 125.32, 121.28, 
118.82, 118.27,66.40,27.59. AnaL Calcd for C14H12FN02S: C, 60.64; H, 4.36; N, 5.05; 
S, 11.56. Found: C, 60.71; H, 4.41; N, 4.96; S, 11.45 
.. -
(±)-3-( 4-Biphenyl-4-yl-hydroxymethyl)-N -methylbenzenesulfonamide (5). 
Dry THF (23.4 mL) was added to N-methylbenzenesulfonamide (2) (1 g, 5.84 mmol) in a 
100-mL flame-dried round bottom flask. Nitrogen was run into the flask, and the flask 
was cooled to 0 °C while stirring. n-Butyllithium (5.84 tTlL of a 2.5 M solution in 
hexanes, 14.6 mmol) was then added to the reaction over 3-4 min and left to stir at 0 °C 
for 25 min. To this mixture was added a solution of 4-biphenylcarboxaldehyde (1.70 g, 
9.34 mmol) and THF (9.34 mL) over 4 min. This was allowed to stir for 45 min. Next, 
HCI (12 mL, 5% solution) was added, and the two resulting layers were separated. The 
organic layer was washed three times with saturated NaCI solution. The aqueous layers 
were all extracted with ether, and all organic layers were combined. The solution was 
dried with magnesium sulfate, the solvent was removed under vacuum, and the product 
was purified by chromatography, yielding 1.41 g (68.4%) of 5. IH NMR (CDCI3): 0 8.00 
(1H, m), 7.46 (l3H, m), 6.72 OH, s), 4.61 OH, m), 2.44 (3H, d); 13C NMR (CDCh): 8 
141.75, 140.83, 140.32, 138.26, 133.04, 130.58, 130.43, 128.85, 127.95, 127.52, 127.46, 
127.23, 127.01, 71.89, 29.38. AnaL Calcd for C2oH19N03S·0.9H20: C, 64.99; H, 5.67; N, 
3.79. Found: C, 64.96; H, 5.65; N, 3.50. 
(±)-3-Biphenyl-4-yl-2-methyl-2,3-dihydrobenzo[d]isothiazole l,l-dioxide (6). 
H2S04 (3 mL) and 5 (200 mg, 0.567 mmol) were combined in a 50-mL round bottom 
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flask. This mixture was then stirred for 1 h. The mixture was poured over ice, rinsing 
the reaction flask with distilled water. This was extracted three times with CH2Ch, and 
all organic fractions were washed with saturated NaCI solution. The solution was dried 
with magnesium sulfate, the solvent was removed under vacuum, and the product was 
purified by chromatography, yielding 66.5 mg (35.0%) of 6. IH NMR (CDCh): 07.87 
(lH, m), 7.49 (l2H, m), 7.09 (lH, m), 2.81 (3H, s); l3C NMR (CDCh): 0 142.07,140.14, 
138.29, 135.53, 134.07, 132.95, 129.32, 128.83, 128.55, 127.80, 127.65, 127.04, 125.01, 
121.07,66.67,27.41. Anal. Calcd for C2oH17N02S·0.7H20: C, 69.02; H, 5.33; N, 4.02. 
Found: C, 69.05; H, 5.27; N, 3.90. 
(±)-2-[(3-Chlorophenyl)hydroxymethyl]-N-methylbenzenesulfonamide (7). 
Dry THF (23.4 mL) was added to N-methylbenzenesulfonamide (2) (1 g, 5.84 mmol) in a 
100-mL flame-dried round bottom flask. Nitrogen was run into the flask, and the flask 
was cooled to 0 °C while stirring. n-Butyllithium (5.84 mL of a 2.5 M solution in 
hexanes, 14.6 mmol) was then added to the reaction over 3--4 min and left to stir at 0 °C 
for 25 min. To this mixture was added a solution of 3-chlorobenzaldehyde (1.06 mL, 
9.34 mmol) and THF (9.34 mL) over 4 min. This was allowed to stir for 45 min. Next, 
HCI (12 mL, 5% solution) was added, and the two resulting layers were separated. The 
organic layer was washed three times with saturated NaCI solution. The aqueous layers 
were all extracted with ether, and all organic layers were combined. The solution was 
dried with magnesium sulfate, the solvent was removed under vacuum, and the product 
was purified by chromatography, yielding 1.644 g (90.3%) of 7. IH NMR (CDCh): 0 
8.01 (lH, m), 7.42 (8H, m), 6.68 (lH, s), 4.54 (lH, d), 2.55 (3H, d); l3C NMR (CDCh): 0 
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143.93,141.26,136.34,134.47,133.19,130.62, 130.04, 129.77, 128.16, 127.92, 127.86, 
125.04,70.93,29.32. 
(±)-3-(3-Chlorophenyl)-2-methyl-2,3-dihydrobenzo[d]isothiazole l,l-dioxide 
(8). H2S04 (3 mL) and 7 (300 mg, 0.962 mmol) were combined in a 50-mL round 
bottom flask. This mixture was then stirred for 1 h. The nlixture was poured over ice, 
rinsing the reaction flask with distilled water. This was extracted three times with 
CH2C}z, and all organic fractions were washed with saturated NaCI solution. The 
solution was dried with magnesium sulfate, the solvent was removed under vacuum, and 
the product was purified by chromatography, yielding 0.220 g (77.7%) of 8. IH NMR 
(CDCh): 07.87 (lH, m), 7.54 (2H, m), 7.36 (3H, m), 7.25 (lH, m), 7.05 (lH, m), 5.16 
(lH, s), 2.79 (3H, s); I3C NMR (CDCh): 0 138.83, 137.58, 135.19, 133.96, 133.13, 
130.50, 129.56, 129.46, 128.10, 128.30, 124.88, 121.26, 66.40, 27.60. Anal. Calcd for 
C14H12CIN02S·0.3H20: C, 56.21; H, 4.24; N, 4.68; S, 10.72. Found: C, 56.26; H, 4.21; 
N, 4.60; S, 10.62. 
(±)-3-[(3-Bromophenyl)hydroxymethyl]-N -methylbenzenesulfonamide (9). 
Dry THF (11.7 mL) was added to N-methylbenzenesulfonamide (2) (0.5 g, 2.92 mmol) in 
a 50-mL flame-dried round bottom flask. Nitrogen was run into the flask, and the flask 
was cooled to 0 °C while stirring. n-Butyllithium (2.92 mL of a 2.5 M solution in 
hexanes, 7.3 mmol) .was then added to the reaction over 3-4 min. and left to stir at 0 °C 
for 25 min. To this mixture was added a solution of 3-bromobenzaldehyde (0.545 mL, 
4.67 mmol) and THF (4.67 mL) over 4 min. This was allowed to stir for 45 min. Next, 
HCI (12 mL, 5% solution) was added, and the two resulting layers were separated. The 
organic layer was washed three times with saturated NaCI solution. The aqueous layers 
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were all extracted with ether, and all organic layers were combined. The solution was 
dried with magnesium sulfate, the solvent was removed under vacuum, and the product 
was purified by chromatography, yielding 560 mg (53.9%) of 9. IH NMR (CDCI3): 8 
7.96 (1H, m), 7.48 (4H, m), 7.28 (4H, m), 6.69 (1H, m), 5.09 (lH, s), 2.55 (3H, s). 
(±)-3-(3-Bromophenyl)-2-methyl-2,3-dihydrobenz.~.~d]isothiazole 1,I-dioxide 
(10). H2S04 (3 mL) and 9 (300 mg, 0.843 mmol) were combined in a 50-rnL round 
bottom flask. This mixture was then stirred for 1 h. The mixture was poured over ice, 
rinsing the reaction flask with distilled water. This was extracted three times with 
CH2Ch, and all organic fractions were washed with saturated N aCI solution. The 
solution was dried with magnesium sulfate, the solvent was removed under vacuum, and 
the product was purified by chromatography, yielding 0.230 g (80.7%) of 10. IH NMR 
(CDCI3): 87.85 (lH, m), 7.53 (4H, m), 7.28 (2H, m), 7.04 (1H, m), 5.15 (1H, s), 2.79 
(3H, s); l3C NMR (CDCh): 8 139.06, 137.53, 133.95, 133.11, 132.37, 130.95, 130.79, 
129.58, 126.74, 124.88, 123.22, 121.21, 66.30, 27.57. Anal. Ca1cd for C14H12BrN02S: C, 
49.72; H, 3.58; N, 4.14; S, 9.48; Br, 23.62. Found: C, 49.64; H, 3.56; N, 4.05; S, 9.50; 
Br,23.70. 
(±)-N-MethyI-2-(2,2,2-trifluoro-l-hydroxy-l-phenyI-ethyI)-benzene-
sulfonamide (11). Dry THF (11.7 mL) was added to N-methylbenzenesulfonamide (2) 
(0.5 g, 2.92 mmol) in a 50-mL flame-dried round bottom flask. Nitrogen was run into the 
flask, and the flask was cooled to 0 °C while stirring. n-Butyllithium (2.92 mL of a 2.5 
M solution in hexanes, 7.3 mmol) was then added to the reaction over 3--4 min. and left 
to stir at 0 DC for 25 min. To this mixture was added a solution of 2,2,2-
trifluoroacetophenone (0.66 mL, 4.67 mmol) and THF (4.67 mL) over 4 min. This was 
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allowed to stir for 45 min. Next, HCl (6 mL, 5% solution) was added, and the two 
resulting layers were separated. The organic layer was washed three times with saturated 
NaCl solution. The aqueous layers were all extracted with ether, and all organic layers 
were combined. The solution was dried with magnesium sulfate, the sol vent was 
removed under vacu~m, and the product was purified by chromatography, yielding 0.835 
g (86.1 %) of 11. IH NMR (CDC13): 08.18 (lH, d), 7.92 (lH, d), 7.56 (6H, m), 6.67 OH, 
s), 2.63 (lH, d), 2.14 (3H, d); l3C NMR (CDCh): 0 138.63, 138.38, 136.65, 133.83, 
132.82,130.35,129.49,129.43,129.07,128.95,128.33, 128.16, 126.89, 122.36,80.53, 
29.27. 
(±)-3-Phenyl-3-trifluoromethyl-3H-benzo[c ][1,2]oxathiole 1,I-dioxide (12). 
H2S04 (3 mL) and 11 (300 mg, 0.904 mmol) were combined in a 50-mL round bottom 
flask. This mixture was then stirred for 1 h. The mixture was poured over ice, rinsing 
the reaction flask with distilled water. This was extracted three times with CH2Ch, and 
all organic fractions were washed with saturated NaCl solution. The solution was dried 
with magnesium sulfate, the solvent was removed under vacuum, and the product was 
purified by chromatography, yielding 0.742 g (93.8%) of 12. IH NMR (CDCh): 07.77 
(6H, m), 7.45 (3H, m); l3C NMR (CDCh): 0 134.38,134.01,132.02,131.89,130.35, 
129.38,129.07,128.33,126.39,125.39,124.65,122.37, 120.31,88.31. Anal. Ca1cd for 
C14H9F303S·0.125 C6H 14: C, 54.50; H, 3.33; N, 0; S, 9.86. Found: C, 54.51; H, 3.17; N, 
0; S, 9.65. 
N-Phenyl benzenesulfonamide (13). NaOH (1.61 g, 40.3 mmol) was dissolved 
in distilled water (32.5 rnL) in a 250-mL round bottom flask. The solution was cooled to 
o °C. Aniline (4.41 mL, 48.4 mmol) was added by syringe, and the mixture was stirred. 
15 
Next, PhS02CI (5.15 mL, 40.4 mmol) was added over 2-3 min. CHClz (32 mL) was 
added to thin the reaction mixture. After 1 h, the reaction was allowed to warm to room 
temperature and then extracted three times with CH2Clz. The organic layers were washed 
with saturated NaCI solution and then dried with magnesium sulfate. The solvent was 
removed under vacuum and purified with chromatography, yielding 8.86 g (94.1 %) of 13. 
tH NMR (CDCb): 07.79 (2H, m), 7.50 (4H, m), 7.21 (2H, m), 7.10 (3H, m). 
(±)-2-(Biphenyl-4-yl-hydroxymethyl)-N-methyl benzenesulfonamide (14). 
Dry THF (23.4 mL) was added to N-phenylbenzenesulfonamide (13) (1 g, 4.29 mmol) in 
a 100-mL flame-dried round bottom flask. Nitrogen was run into the flask, and the flask 
was cooled to 0 °C while stirring. n-Butyllithium (4.29 mL of a 2.5 M solution in 
hexanes, 10.7 mmol) was then added to the reaction over 3-4 min and left to stir at 0 °C 
for 25 min. To this mixture was added a solution of benzaldehyde (0.70 mL, 6.86 mmol) 
and THF (9.34 mL) over 4 min. This was allowed to stir for 45 min. Next, HCI (12 mL, 
5% solution) was added, and the two resulting layers were separated. The organic layer 
was washed three times with saturated NaCI solution. The aqueous layers were all 
extracted with ether, and all organic layers were combined. The solution was dried with 
magnesium sulfate, the solvent was removed under vacuum, and the product was purified 
by chromatography, yielding 1.27 g (87.3%) of 14. IH NMR (CDCb): 07.73 (lH, m), 
7.25 (13H, m), 6.89 .<lH, s), 4.68 (lH, s), 3.35 (lH, d), 2.03 (lH, s). 
(±)-3-Biphenyl-4-yl-2-methyl-2,3-dihydrobenzo[d]isothiazole 1,I-dioxide (15). 
HBr (10 mL, 48%) and 14 (300 mg, 0.885 mmol) were combined in a 25-mL round 
bottom flask. This mixture was then refluxed for 4 h. The mixture was poured over ice, 
rinsing the reaction flask with distilled water. This was extracted three times with 
16 
CH2Ch, and all organic fractions were washed with saturated NaCI solution. The solution 
was dried with magnesium sulfate, the solvent was removed under vacuum, and the 
product was purified by chromatography, yielding 0.152 g (53.5%) of 15. IH NMR 
(CDCh): 07.86 (lH, m), 7.32 (l3H, m), 6.04 (lH, s); l3C NMR (CDCh): 0 137.38, 
137.20,134.77,133.50,133.13,129.46,129.35, 129.04, 128.79, 127.47, 126.04, 125.04, 
123.81, 121.12, 65.32. Anal. Calcd for C19H15N02S: C, 71.01; H, 4.70; N, 4.36; S, 9.98. 
Found: C, 70.79; H, 4.76; N, 4.30; S, 9.85. 
References 
1) Levy, J. A. Microbiol. Rev. 1993, 57(1), 183-289. 
2) Williams, T. M.; Ciccarone, T. M.; MacTough, S. C.; Rooney, C. S.; Balani, S. K.; 
Condra, J. H.; Emini, E. A.; Goldman, M. E.; Greenlee, W. J.; Kauffman, L. R.; O'Brien, 
J. A.; Sardana, V. V.; Schleif, W. A.; Theoharides, A. D.; Anderson, P. S. J. Med. Chern. 
1993,36,1291-1294. 
3) Gordon, 1.; King, P.; Wingert, P.; Gegax, T. T.; Miller, S.; Kalb, C. Newsweek 1996, 
66-73. 
4) AIDS epidemic update: December 1998; Vol. 1999. 
5) Erickson, J. W.; Burt, S. K. Annu. Rev. Pharmacol. Toxicol. 1996,36,545-71. 
6) Barnard, J.; Borkow, G.; Parniak, M. A. Biochemistry 1997, 36, 7786-7792. 
7) Cushman, M.; Golebiewski, W. M.; Graham, L.; Turpin, 1. A.; Rice, W. G.; Fliakas-
Boltz, V.; Buckheit, R. W. J. Med. Chem. 1996,39, 3217-3227. 
8) Romero, D. L.; Olmsted, R. A.; Poel, T. J.; Morge, R. A.; Biles, C.; Keiser, B. J.; 
Kopta, L. A.; Friis, 1. M.; Hosley, 1. D.; Stefanski, K. 1.; Wishka, D. G.; Evans, D. B.; 
17 
Morris, J.; Stehle, R. G.; Sharma, S. K.; Yagi, Y.; Voorman, R. L.; Adams, W. 1.; 
Tarpley, W. G.; Thomas, R. C. 1. Med. Chem. 1996, 39, 3769-3789. 
9) Watanabe, H.; Gay, R. L.; Hauser, C. R.I. Org. Chem. 1968, 33, 900-903. 
18 
Appendix 
90006 '-
III 
co 
III 
III 
tV 
sr.ts§ t 
lhBt'c 
d lUi f 
III 
~ 
co 
,...: 
III 
,...: 
Wdd 
\ 
o 
.; 
111 
111 
--~~-=-,=:::i:H::i 111 
~ 
o 
..;. 
o 
0 
N 
lUS 'it 
0 
M 
"':t 
0 
... 
u. 
0 
In 
0 
(,Q 
ou'h 
0 
....... 
0 
CD 
0 
Q') 
oX: 
00... 
-0... 
0 
Hi:ltl ;;;--- 0 N 
0 
M 
Tl'l"uci 0 ... 
I-
(.) 
,:) 0 
Cl In 
0 
a: 
0... 
0 
a: 0 
0 (,Q 
~ 
..J 
U. 
I 
..... 
0 
0 ....... 
lLJ 
N 
..J 
(.) 
>- 0 
u CD 
lL. 
0 
%. 
0 0 
en Q') 
a: 
< 
(.) 
Wdd 
PPM 
C':I 
-< 
C':I 
r 
N 
fTI 
0 
.,.. 
J 
"'Tl 
r 
c 
0 
::c 
0 
" '-----------------~ ::c 0 0 C 
t') 
-t 
~-------------------~ 
L .... ___ --. s. On41 
2.82859 
t.139U 
o 
'../ r'": 
, .. : c·) c· 
~.:; :-, ('i (.) 
_> I,,) t·.' 
(J t·) t::I 
I·' '../ • ., 
u t·) 
'- ~ n ~~ i~; 
PPI1 
5.2712' 
-' t:;UU 
""" !:1UU 
1.,,751 
c: 
% 
(') 
~ 
(') 
r-
N 
ITI 
o 
CO 
." 
:% 
ITI 
% 
~ 
r-
'-
% 
I 
I 
en 
PPH 
c:: 
'Z 
n 
-< 
n 
eD 
0 
r-
N 
m 
0 
CII 
." 
::z: 
m 
'Z 
-< 
.... 
'-
::r 
I 
I 
en 
ZI 'U 
21 311 
1,2S9U 
. o us 2.. 
.OQo5.J 
o 
tTl 
0 
.,.. 
0 
t.o) 
0 
N 
0 
o 
o 
co 
o 
en 
o 
tTl 
o 
N 
o 
PPM 
(') 
-< 
(') 
r 
N 
rn 
0 
tl) 
HZ. 07 + ." 
UP,1H :z: rn 
138.268 :z 
-< 
53 r 
." 
::0 
0 
0 
C 
C') 
-4 
121.072 
771'51~ 
68.671 
27,+1+ 
~~ ~~ ;:: ~J :~~ :!~ . ~H :.; 
(-J 
:. :.: 
Welel 
ttf'lt 
tts dZ 
n 
...J 
0 
Q 
0 
% 
0 
n 
Q 
I.t.I 
N 
" 
C 
...J 
0 iSl; III >-
0 Itt 'ttl z 
:::::I 
...J 
0 
I 
n , 
z: 
..., 
Wdd 
/' 
i'" 
<:> 
N 
<:> 
.... 
<:> 
o 
0 
N 
0 
n 
<:> 
0 
11'\ 
c 
W 
N 
..J 
(J 
>-(J 
w 
c 
>-
J: 
w 
C 
..J 
ct 
N 
Z 
W 
a::J 
o 
a: 
o 
..J 
J: 
(J 
I 
en 
6SIS9'1 
!iaiDZ'~ tau" 
Hdd 
:7"" 
G 
0 
N 
In 
N 
0 
C"'I 
o 
In 
In 
co 
Las'lt 
19t '99 
II 
IIZS'ZCI _ 
1'1S • 9t l 
<"t 
J: 
U 
I 0, z ~/ 
.....-(J) 
0;""'-
co 
o 
o 
N 
o 
II'! 
o 
to 
o 
01 
oX:: 
o a.. 
-a.. 
o 
o 
N 
o 
ao 
o 
01 
iflU;- 7 
~ 
E;;: 
"RTIT'1----
Wdd 
o 
..;. 
o 
..... 
In 
..... 
8.5 
..... 
",I 
8.0 1.5 
1 ~ , 
10 
Br 
7.9040 7.7966 AREA .~2 
7.6307 7.4433 AREA ~ 4.137 
7.3574 7.2091 AREA 2.160 
7.0880 6.9962 AREA .~50 
5. 1633 5.1320 AREA ~ .917 
2.8110 2.8110 AREA .018 
2.8110 2.7505 AREA 3.000 
iii i I j I I' ii' 'I iii Iii Iii I. iii 'I iiI i I I' '-'-I--'~--l~ Imml 
1.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 Z.O 1.5 1.0 .5 0.0 
PPH 
PPM 
+7.568 
~. l.-
..... 
\* ~ 
. 
;: ~ 
o 
PPM 
!:HfU 
1.15355 
- 009&7 
N 
'Z 
o 
PPM 
21. 273 
c 
:z 
n 
-< 
n 
r 
N 
m 
o 
-j 
::Il 
I 
." 
r 
C 
o 
::Il 
o 
Co.. 
:.r 
! 
! 
N 
N 
o 
a: 
o 
:;) 
..J 
u.. 
a: 
l-
e 
I.IJ 
N 
U:H 
ttC'U-
C§Z'~II 
r 
.0-
~ 
-
/. ...... 
://.: 
./. 
..I 
N 
.,.. 
n 
u. 
bO g~u{ ~!J If ~ 
-
. , 
l 
~ 
.. " 
iii 
: 
~ 
.: 
r 
.: 
~,.. 
~ 
~ 
~ 
'i'" 
'f: "l~ 
...,.....~ 
! 
"'l 
\.LV ~ 
e,;-=s 
~ 
""'";r-
t" 
- .... 
~t 
..::=I 
!: 
;r 
~ 
' .. 
=~ 
-: 
r 
i 
i 
~ 
r 
:-
o 
N -, 
roo 
t-
I-
I-
o 
.... 
o 
.... 
o 
II) 
o 
CoO 
w 
o 
2: 
« 
z 
o 
LL. 
-I 
;:;, 
(/) 
w 
z 
W 
N 
Z 
W 
ID 
-I 
>-
Z 
W 
:x: 
a.. 
a&tn! -
&UD!) -
sa tlO 
9tat's 
9 
Wad 
........... 
./ 
l 
~ 
~ 
fI 
'1/ 
'If 
fJI 
'H 
--, 
-
." 
{ 
-
.c o 
a.. 
J: M ,.-- ..;. 
~ 't'"" 
0 (J) 
b 
-
) 
III 
) ,..: 
1 
ILl 
0 
>-
:J: 
ILl 
0 
....J 
ct 
N 
Z 
ILl 
III 
....J 
>-
Z 
ILl 
:J: 
Il. 
0 
ILl 
N 
....J 
c.J 
>-
c.J 
z 
:::> 
99t99 · 
lun:1 )= 
Hallo'l 
SIUO't 
tun i& >-
8l6SC'& 
OUl9 l' 
l' 
Wdd 
.s:: '¢ 
Q. .... 
~~a, ~ (J) " 
~ Ii 
o 
.; 
o 
o 
N 
U") 
N 
o 
..;. 
o 
o 
o 
U") 
" 
0 
ro 
U") 
~ 
tlho 
-.-
6 
"'-.:. 
-~~ 
-~ 
//1 
II 
Yr 
{II 
fl 
'I 
-, 
t II 
•• ' . ., .~:. (;1 '.' , • 
~~ ~~~~ ~.; :~ ::~ ~5 
.... 
~ " t • ..-,. !: 1 
f:~ ~ ~ (~~ ~: ~:~ 
.. "l') C'I r-. ;'1-~.J .. :0- ..... =- .j .::-
........ 
j ..... !" i ... i'"' ,"J t.) 
~f~~~;:~~ 
~: ,..:' !.: ,.: ,.j :.;) 
j 
-
I.f') 
x: 
I.f')a... 
,a... 
,..., 
I 
i 
U) 
7 
I 
::c 
..., 
I.&J 
o 
>-
~ 
t.IJ 
o 
....I 
"" N :z. 
t.IJ 
CD 
~ 
a... 
o 
I.&J 
N 
....I 
c.J 
>-
c.J 
Wdd 
<:> 
In 
<:> 
" 
